Compare Aurobindo Pharma with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ELDER PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ELDER PHARMA AUROBINDO PHARMA/
ELDER PHARMA
 
P/E (TTM) x 9.4 -0.2 - View Chart
P/BV x 1.7 0.1 1,724.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AUROBINDO PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ELDER PHARMA
Jun-14
AUROBINDO PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs830380 218.4%   
Low Rs527188 280.4%   
Sales per share (Unadj.) Rs333.9491.2 68.0%  
Earnings per share (Unadj.) Rs40.4-3.2 -1,268.4%  
Cash flow per share (Unadj.) Rs51.814.4 359.2%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.1376.5 63.0%  
Shares outstanding (eoy) m585.9120.54 2,852.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.00.6 351.5%   
Avg P/E ratio x16.8-89.3 -18.8%  
P/CF ratio (eoy) x13.119.7 66.5%  
Price / Book Value ratio x2.90.8 379.4%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5695,833 6,815.4%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,8492,179 1,186.3%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,63610,089 1,939.1%  
Other income Rs m1,553257 605.3%   
Total revenues Rs m197,18910,346 1,906.0%   
Gross profit Rs m39,519-792 -4,990.5%  
Depreciation Rs m6,680361 1,848.7%   
Interest Rs m2,6262,756 95.3%   
Profit before tax Rs m31,767-3,653 -869.6%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8813,713 -23.7%   
Tax Rs m7,269125 5,807.8%   
Profit after tax Rs m23,645-65 -36,182.1%  
Gross profit margin %20.2-7.8 -257.4%  
Effective tax rate %22.9-3.4 -667.8%   
Net profit margin %12.1-0.6 -1,865.9%  
BALANCE SHEET DATA
Current assets Rs m153,6459,240 1,662.8%   
Current liabilities Rs m120,4299,998 1,204.6%   
Net working cap to sales %17.0-7.5 -226.1%  
Current ratio x1.30.9 138.0%  
Inventory Days Days13546 291.9%  
Debtors Days Days6460 106.3%  
Net fixed assets Rs m103,90910,124 1,026.4%   
Share capital Rs m586206 284.8%   
"Free" reserves Rs m138,3225,582 2,477.9%   
Net worth Rs m138,9087,734 1,796.2%   
Long term debt Rs m1,8004,889 36.8%   
Total assets Rs m264,54422,882 1,156.1%  
Interest coverage x13.1-0.3 -4,026.3%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.4 167.7%   
Return on assets %9.911.8 84.4%  
Return on equity %17.0-0.8 -2,014.4%  
Return on capital %23.822.3 106.8%  
Exports to sales %49.63.0 1,633.1%   
Imports to sales %18.80.4 4,396.2%   
Exports (fob) Rs m97,091307 31,667.1%   
Imports (cif) Rs m36,74143 85,246.6%   
Fx inflow Rs m97,316307 31,740.5%   
Fx outflow Rs m40,589125 32,393.6%   
Net fx Rs m56,727181 31,289.1%   
CASH FLOW
From Operations Rs m16,22011,754 138.0%  
From Investments Rs m-28,768-561 5,132.6%  
From Financial Activity Rs m19,191-6,762 -283.8%  
Net Cashflow Rs m6,6564,432 150.2%  

Share Holding

Indian Promoters % 54.1 39.6 136.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 16.8 164.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 36.1 28.3%  
Shareholders   69,601 16,479 422.4%  
Pledged promoter(s) holding % 8.6 77.6 11.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,028 Points; Oil & Gas, FMCG and Metal Stocks Rally(Closing)

Indian share markets continued to trade in the green during closing hours and ended their day on a strong note, tracking global cues.

Related Views on News

DR. REDDYS LAB Surges by 5%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

DR. REDDYS LAB share price has surged by 5% and its current market price is Rs 3,148. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are DR. REDDYS LAB (up 5.0%) and ASTRAZENECA PHARMA (up 7.5%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and DR. LAL PATHLABS LTD (down 0.7%).

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 31, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS